vTv Therapeutics Updates on Phase 3 Diabetes Program and Extends Cash Runway

summarizeSummary

vTv Therapeutics released an updated investor presentation detailing progress on its Phase 3 Type 1 Diabetes drug, Cadisegliatin, and confirming a cash runway extending beyond key clinical data readouts.

check_boxKey Events

• Phase 3 Clinical Trial Update

  The company's lead asset, Cadisegliatin, is in Phase 3 development for Type 1 Diabetes, with CATT1 trial enrollment expected to complete by Q3 2026. Cadisegliatin has FDA Breakthrough Therapy Designation.

• Extended Cash Runway

  vTv Therapeutics reported $88.9 million in cash as of December 31, 2025, with an additional $20.0 million received on February 2, 2026, providing a cash runway well past the CATT1 topline data readout.

• Comprehensive Pipeline Overview

  The presentation also highlighted other clinical-stage assets in immunology/inflammation, metabolism, and oncology, including TTP273 (oral GLP-1 agonist) and HPP971/HPP3033 (Nrf2/Bach1 Modulator).

auto_awesomeAnalysis

vTv Therapeutics filed an updated investor presentation highlighting significant progress for its lead asset, Cadisegliatin, which is in Phase 3 development for Type 1 Diabetes. The drug has FDA Breakthrough Therapy Designation and is positioned as a potential first oral adjunctive therapy for T1D in the U.S. The company expects CATT1 trial enrollment to complete by Q3 2026. Critically, the presentation also provides a positive financial update, stating that $88.9 million in cash as of December 31, 2025, plus an additional $20.0 million received on February 2, 2026, provides a cash runway extending well past the CATT1 topline data readout. This update on clinical milestones and financial stability is important for investors.